Lantern Pharma (LTRN) investor relations material

Executive summary

• Achieved a 27% year-over-year reduction in net loss for Q1 2026 while advancing multiple precision oncology programs and launching the withZeta.ai AI platform commercially.

• Focused on AI-driven oncology drug development, with three clinical-stage candidates and an ADC program leveraging the RADR® platform for targeted therapies.

• Announced plans to spin off the withZeta.ai AI platform into an independent entity to access dedicated funding and realize separate valuation multiples.

• No revenue recognized for the quarter; operations funded primarily by equity sales.

• Strengthened balance sheet with $4.4 million in new financing, extending operating runway into Q1 2027.

Financial highlights

• Q1 2026 net loss was $3.33 million ($0.30/share), down from $4.54 million ($0.42/share) in Q1 2025, a 27% reduction.

• Total operating expenses decreased to $3.41 million from $4.77 million year-over-year, driven by a 47% reduction in R&D expenses.

• R&D expenses decreased to $1.73 million from $3.26 million year-over-year.

• General and administrative expenses rose 11% to $1.68 million, driven by higher patent, salary, and business development costs.

• Cash, cash equivalents, and marketable securities totaled $6.3 million as of March 31, 2026, with an additional $4.4 million raised in May 2026.

Outlook and guidance

• Liquidity, including proceeds from a May 2026 offering, expected to fund operations until mid-Q1 2027.

• Substantial additional capital will be needed beyond that period to continue R&D and clinical trials.

• Additional HARMONIC™ trial data readouts and new clinical trial initiations for LP-184 and STAR-001 planned for 2026.

• Continued commercialization and expansion of withZeta.ai, including conversion of demo users to commercial contracts.

• Plans to pursue further capital raises, grants, and potential commercial credit facilities.